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Background: Acinetobacter Baumannii and Pseudomonas
aeruginosa are the nosocomial pathogens in burn patients. Both
are instrinsically resistant to a wide range of antibiotics and are
able to become resistant to any antimicobial agents. From a clinical
perspective, XDR P. aeruginosa and A. baumannii isolates that
present resistant to carbapenems represent the most challenging
pathogens, since carbapenems are the most potent agents against
these organisms. Moreover, a few therapeutic options remain
available for the treatment of XDR P. aeruginosa and A. baumannii
isolates, and no new agents able to overcome the known resistance
mechanisms have been developed. Therefore, the optimal use of
the few remaining therapeutic options is important in current
situation. However, there are few studies that estimate the clinical
outcomes of various available therapeutic options for XDR P.
aeruginosa and A. baumannii bacteremia.
Methods & Materials: This study was case series in single burn
center. We collected patients data for 3 years from 2010 January
1 to 2012 December 31. We included burn ICU patients reported
with XDR P. aeruginosa and A. baumannii bacteremia through blood
culture study (Criteria for deﬁning XDR: non-susceptible to ≥ 1
agent in all but ≤ 2 categories). Primary outcome was 7days mor-
tality and 2ndary endpotint was eradication of bacteremia within
3-4days after appropriate antibiotic use.
Results: During 3 years, cases of XDR P. aeruginosa are 32
patients and XDR A. baumannii are 24 patients. Overall 7 days mor-
tality was 53.1% of XDR P. aeruginosa bacteremia and 37.5% ofXDR
A. baumannii.
In XDR P. aeruginosa cases, colistinmonotherapy group survived
only 52.4%(11/21case) but colistin and carbapenem combination
group survived 71,4%(5/7case). In XDR A. baumannii cases, colistin
monotherapy group survived 71.4%(5/7case), colistin and tigecy-
cline combination group survived 71,4%(5/7case) and carbapenem
monotherapy group survived 50%(2/4case).
Conclusion: In the case of XDR P. aeruginosa bacteremia, a com-
bination of the carbapenemwith colistinwould be preferred rather
than the exclusive use of the colistin. In the case of XDR A. bau-
mannii bacteremia, use of the tigecycline or the meropenem alone
would be avoided.
Fig. 1. Basal characteristics.
Fig. 2. clinical outcomes of XDR P.aeruginosa bacteremia in burn patienst.
Fig. 3. clinical outcomes of XDR A.baumanii bacteremia in burn patienst.
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